PM 01183: Clinical Trials

31 trials of PM 01183, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 7 recruiting, 4 unknown, 3 withdrawn. 31 Phase 1, 16 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 131Completed 13, Recruiting 7, Unknown 4, Withdrawn 3, Active not recruiting 2, Not yet recruiting 1, Terminated 1
Phase 216Recruiting 5, Unknown 3, Withdrawn 3, Active not recruiting 2, Completed 2, Not yet recruiting 1

Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMisty Shields162027-01-012026-10-15
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingVA Office of Research and Development1662026-02-232026-03-11
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage
Phase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1002025-12-312025-08-26
Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma
Phase 1 / Phase 2WithdrawnUniversity of California, San Francisco2024-10-312024-11-18
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
Lurbinectedin, Dostarlimab - Endometrial Cancer
Phase 1 / Phase 2WithdrawnVall d'Hebron Institute of Oncology2024-05-012025-04-01
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
Phase 1 / Phase 2RecruitingPhanes Therapeutics2032023-09-052026-07-15
Lurbinectedin in FET-Fused Tumors
Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
Phase 1 / Phase 2RecruitingChildren's Hospital of Philadelphia632023-07-272026-09-02
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Paclitaxel, Bevacizumab, Lurbinectedin - Ovarian Cancer
Phase 1RecruitingM.D. Anderson Cancer Center342023-07-122026-08-20
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
Lurbinectedin - Advanced Soft-tissue Sarcoma
Phase 1 / Phase 2UnknownERLINDA M GORDON402023-06-072024-07-05
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Phase 1 / Phase 2RecruitingJazz Pharmaceuticals602023-05-232026-11-05
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Lurbinectedin, Palliative Radiation Therapy - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1RecruitingEmory University222022-07-272025-10-31
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Lurbinectedin, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Phase 1 / Phase 2Active not recruitingMassachusetts General Hospital622022-02-042026-08-27
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride - Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2021-09-152022-02-10
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)372021-06-012026-03-17
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Lurbinectedin - Advanced Solid Tumor, Hepatic Impairment
Phase 1UnknownPharmaMar242021-03-092023-11-27
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Lurbinectedin, Bosentan - Advanced Solid Tumor
Phase 1CompletedPharmaMar112021-01-142025-09-16
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Lurbinectedin for injection - Advanced Solid Tumor
Phase 1CompletedLuye Pharma Group Ltd.322020-11-242024-06-10
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Nivolumab, Ipilimumab, Lurbinectedin - Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer
Phase 1TerminatedH. Lee Moffitt Cancer Center and Research Institute92020-11-232024-04-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration - Advanced Solid Tumors
Phase 1CompletedPharmaMar142020-10-072025-09-02
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
Lurbinectedin, Pembrolizumab - Small Cell Lung Carcinoma
Phase 1 / Phase 2CompletedAntonio Calles Blanco282020-09-212025-06-04

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Small Cell Lung Carcinoma (8)  ·  Neoplasms (5)  ·  Breast Neoplasms (3)  ·  Endometrial Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Sarcoma (3)  ·  Sarcoma, Ewing (3)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Neuroendocrine Tumors (2)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Desmoplastic Small Round Cell Tumor (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)

Sponsors

PharmaMar (12)  ·  M.D. Anderson Cancer Center (2)  ·  Antonio Calles Blanco (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Children's Hospital of Philadelphia (1)  ·  ERLINDA M GORDON (1)  ·  Emory University (1)  ·  Fundacion Oncosur (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Jazz Pharmaceuticals (1)  ·  Luye Pharma Group Ltd. (1)  ·  Massachusetts General Hospital (1)  ·  Misty Shields (1)  ·  National Cancer Institute (NCI) (1)  ·  Phanes Therapeutics (1)

Countries

United States (17)  ·  Spain (12)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)

Top investigators

Rubin Lubomirov, MD, PhD (2)  ·  Alberto A Chiappori, MD (1)  ·  Andres Poveda, MD (1)  ·  Anish Thomas, M.D. (1)  ·  Antonio Calles (1)  ·  Erlinda M Gordon, MD (1)  ·  Gregory Cote, M.D. Ph.D (1)  ·  Josep Tabernero, MD (1)  ·  Kristin Higgins, MD (1)  ·  Mark Ratain, MD (1)  ·  Misty D Shields, MD, PhD (1)  ·  Robert S Benjamin (1)  ·  Santiago Ponce, MD (1)

Results publications

PMID 33914350, PMID 24563480, PMID 33704620, PMID 34453241, PMID 37491889, PMID 38351146, PMID 39938593, PMID 40963055, PMID 41791703, PMID 42081171

NIH funding

P30CA138292 (1)